NasdaqGM:ARDXBiotechs
Ardelyx (ARDX) Is Down 16.3% After Issuing Higher 2026 Product Revenue Guidance and Patent Update
In February 2026, Ardelyx, Inc. reported full-year 2025 revenue of US$407.32 million, up from US$333.62 million, while net loss widened to US$61.6 million, and issued 2026 revenue guidance for IBSRELA of US$410–US$430 million and XPHOZAH of US$110–US$120 million.
Alongside this update, Ardelyx highlighted strong growth in IBSRELA sales, new patents extending protection to 2042, and ongoing late-stage development efforts that analysts cite as reinforcing the company’s longer-term product and...